中国生物科技服务(08037)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

08037 中国生物科技服务

未开盘 08-20 15:58:28

0.615

+0.000

0.00%

最高0.615	最低0.615	成交量7.00万
今开0.615	昨收0.615	日振幅0.00%
总市值6.00亿	流通市值6.00亿	总股本9.76亿
成交额4.31万	换手率0.01%	流通股本9.76亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"08037","market":"HK","secType":"STK","nameCN":"中国生物科技服务","latestPrice":0.615,"timestamp":1787212708174,"preClose":0.615,"halted":0,"volume":70000,"delay":0,"changeRate":0,"floatShares":975731150,"shares":975731150,"eps":-0.070488,"marketStatus":"未开盘","change":0,"latestTime":"08-20 15:58:28","open":0.615,"high":0.615,"low":0.615,"amount":43050,"amplitude":0,"askPrice":0.635,"askSize":5000,"bidPrice":0.605,"bidSize":25000,"shortable":0,"etf":0,"ttmEps":-0.070488,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787275800000},"marketStatusCode":0,"adr":0,"listingDate":1087401600000,"exchange":"SEHK","adjPreClose":0.615,"openAndCloseTimeList":[[1787189400000,1787198400000],[1787202000000,1787212800000]],"volumeRatio":0.374331550581944,"lotSize":5000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/08037","defaultTab":"news","newsList":[{"id":"2659150458","title":"中国生物科技服务(08037.HK)完成出售标准病理检验所及卓纪保健的全部已发行股本","url":"https://stock-news.laohu8.com/highlight/detail?id=2659150458","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659150458?lang=zh_cn&edition=full","pubTime":"2026-08-13 21:42","pubTimestamp":1786628575,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1219","BK1511","08037"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159927325","title":"中国生物科技服务（08037）完成出售香港实验室检测业务  聚焦硼中子俘获治疗产业链","url":"https://stock-news.laohu8.com/highlight/detail?id=1159927325","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159927325?lang=zh_cn&edition=full","pubTime":"2026-08-13 21:36","pubTimestamp":1786628164,"startTime":"0","endTime":"0","summary":"中国生物科技服务控股有限公司8月13日公告，公司已于同日完成出售标准病理检验所有限公司及卓纪保健有限公司全部已发行股本的主要交易。公告显示，买卖协议所载的所有先决条件均已满足，交易正式交割后，上述两家公司不再为中国生物科技服务附属公司，其财务业绩亦将不再并入集团合并报表。公司表示，此次剥离持续亏损的香港实验室检测业务，是落实业务战略转型的重要一环。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08037"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659184539","title":"中国生物科技服务预计2026年中期净利润不少于1500万港元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2659184539","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659184539?lang=zh_cn&edition=full","pubTime":"2026-08-13 08:59","pubTimestamp":1786582740,"startTime":"0","endTime":"0","summary":"8月12日，中国生物科技服务（08037）发布公告，预计在截至2026年6月30日的6个月内，集团将录得不少于1500万港元的净利润，而在截至2025年6月30日的同期则为约3700万港元的净亏损。预计由亏损净额转为盈利的主要原因是可转换债券可能出现的非现金及未变现公平值收益介于7700万港元至8700万港元之间。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608133839948859.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608133839948859.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["08037"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658903756","title":"中国生物科技服务(08037.HK)发盈喜 预计上半年溢利净额不少于1500万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2658903756","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658903756?lang=zh_cn&edition=full","pubTime":"2026-08-12 22:16","pubTimestamp":1786544180,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1219","08037","BK1511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167031144","title":"中国生物科技服务（08037）定于8月28日审议截至6月30日止半年业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1167031144","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167031144?lang=zh_cn&edition=full","pubTime":"2026-08-12 22:15","pubTimestamp":1786544141,"startTime":"0","endTime":"0","summary":"中国生物科技服务控股有限公司（股票代码：08037）8月12日公告称，公司董事会已决定于2026年8月28日（星期五）召开会议，审议并批准公司及其附属公司截至2026年6月30日止六个月的未经审计简明综合中期业绩，并讨论派发股息事宜（如有）。\n公告披露，董事会目前由六名董事组成，包括三名执行董事刘小林先生（主席）、黄嵩博士及尹燁博士，以及三名独立非执行董事鄢国祥先生、郭圆濤博士和张晓博士。\n根据公告，该文件已按照香港联交所GEM上市规则发布，自刊登之日起将在联交所网站及公司官网分别公开至少七天。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08037"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167667219","title":"中国生物科技服务（08037）发盈利预告：2026财年中期预计净赚不少于1,500万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1167667219","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167667219?lang=zh_cn&edition=full","pubTime":"2026-08-12 22:10","pubTimestamp":1786543828,"startTime":"0","endTime":"0","summary":"中国生物科技服务控股有限公司8月12日公告，根据对集团截至2026年6月30日止六个月的未经审核综合管理账目之初步评估，公司预计将录得不少于1,500万港元的溢利净额；而上年同期则录得约3,700万港元的亏损净额，实现由亏转盈。公司表示，相关数据基于管理层初步审阅结果，未经审核委员会审阅，最终中期业绩预计将于2026年8月底公布。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08037"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153510377","title":"中国生物科技服务预期中期净利润主要来自可换股债券公允价值收益，金额约7700万至8700万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1153510377","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153510377?lang=zh_cn&edition=full","pubTime":"2026-08-12 22:09","pubTimestamp":1786543749,"startTime":"0","endTime":"0","summary":"中国生物科技服务（08037.HK）预期，其中期净利润将主要来自一笔可换股债券的公允价值收益。该收益规模预计在7700万至8700万港元之间。公司强调，这笔非现金性质的收益，成为推动本期业绩实现盈利的关键因素。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08037","BK1511","BK1219"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190494426","title":"中国生物科技服务预期2026年上半年净利润不低于1500万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1190494426","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190494426?lang=zh_cn&edition=full","pubTime":"2026-08-12 22:09","pubTimestamp":1786543749,"startTime":"0","endTime":"0","summary":"中国生物科技服务（CH BIOTECH SER）发布公告，预期截至2026年6月30日止六个月内，公司将录得净利润不少于1500万港元。这一业绩预期反映出公司在生物科技领域的持续增长动力。值得注意的是，相较于去年同期，这一盈利指引标志着公司经营状况的显著改善。市场分析人士认为，这主要得益于公司在生物医药研发及服务板块的强劲表现。具体财务数据将于中期业绩报告中正式披露，届时投资者可进一步审视公司的盈利质量与现金流状况。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1219","08037","BK1511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658928935","title":"中国生物科技服务(08037.HK)构建BNCT“药-械-医”全闭环 产业模式全面升级","url":"https://stock-news.laohu8.com/highlight/detail?id=2658928935","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658928935?lang=zh_cn&edition=full","pubTime":"2026-08-12 11:25","pubTimestamp":1786505111,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1219","BK1511","08037"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658944957","title":"中国生物科技服务称与Stella Pharma就硼中子治疗药物在中国商业化订立协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2658944957","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658944957?lang=zh_cn&edition=full","pubTime":"2026-08-12 08:25","pubTimestamp":1786494326,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["08037","BK1511","BK1219"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161506734","title":"中国生物科技服务（08037）落实Steboronine®在华布局 与Stella Pharma签署10年独家商业化协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1161506734","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161506734?lang=zh_cn&edition=full","pubTime":"2026-08-12 08:20","pubTimestamp":1786494039,"startTime":"0","endTime":"0","summary":"中国生物科技服务控股有限公司8月12日发布自愿公告称，公司与STELLA PHARMA CORPORATION在2026年8月11日签订关于硼中子治疗药物Steboronine在中国开发及商业化的主合作协议。该合作基于双方于2025年5月8日签署的谅解备忘录，标志双方合作进入具法律约束力的新阶段。若Stella Pharma未能在签署日起10年内获得NMPA批准，协议将于期满自动终止。中国生物科技服务表示，与Stella Pharma的深入合作有望加速Steboronine在中国的研发和商业化进程，进一步夯实集团在硼中子治疗上游产业的布局。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08037"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657017695","title":"中国生物科技服务(08037)：华大松禾投资已经完成 鹏博(海南)由华大松禾持有6.25%权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2657017695","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657017695?lang=zh_cn&edition=full","pubTime":"2026-08-07 12:19","pubTimestamp":1786076378,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物科技服务(08037)发布公告，有关华大松禾投资的相关事宜。于补充协议内所载的所有先决条件均已经获履行，而华大松禾投资已经完成。于本公告日期，鹏博(海南)由华大松禾持有6.25%权益。鹏博(海南)将仍然为本公司的非全资附属公司，而鹏博(海南)的财务报表将会继续合并入本集团的财务报表。交易完成提升鹏博(海南)的企业形象及其资本基础。其标志着华大松禾对硼中子俘获治疗中心未来发展，以及本集团致力于为有需要的癌症患者提供硼中子俘获治疗服务的承诺的信心。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477190.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1511","08037","BK1219"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174342235","title":"中国生物科技服务（08037）完成附属公司融资 华大松禾持股6.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=1174342235","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174342235?lang=zh_cn&edition=full","pubTime":"2026-08-07 12:10","pubTimestamp":1786075826,"startTime":"0","endTime":"0","summary":"中国生物科技服务8月7日公告称，公司此前披露的有关华大松禾投资入股全资附属公司——鵬博（海南）健康產業投資有限公司的相关先决条件已全部达成，交易现已正式完成。鵬博（海南）仍为中国生物科技服务的非全资附属公司，其财务报表将继续并入集团财务报表。公司指出，完成本次投资将有助于提升鵬博（海南）的企业形象及资本基础。公司重申，公告内容已根据香港联交所GEM上市规则披露，确保相关信息真实、准确及完整。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08037"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114605157","title":"中国生物科技服务发布2026年7月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1114605157","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114605157?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:46","pubTimestamp":1785833193,"startTime":"0","endTime":"0","summary":"中国生物科技服务控股有限公司于2026年8月4日发布截至2026年7月31日的股份变动月报。公告显示，报告期内公司注册股本及已发行股本保持不变，股本结构总体稳定。根据月报披露信息，公司的法定/注册股本仍为2,000,000,000股普通股，每股面值为HKD0.1，总额HKD200,000,000。报告期末已发行股份为975,731,150股，与上月底相比无变化，库存股份数量始终为0股。尽管存在上述可换股债券，本月并无新增股份发行、购回或注销和库藏股变动。公告由执行董事刘小林签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08037"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656415329","title":"中国生物科技服务(08037.HK)附属于第22届日本中子捕捉疗法学会学术大会发表硼中子治疗初期随访结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2656415329","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656415329?lang=zh_cn&edition=full","pubTime":"2026-08-03 15:54","pubTimestamp":1785743678,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1219","BK1511","08037"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656403483","title":"中国生物科技服务：硼中子治疗首批10例患者三个月随访有效率达80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656403483","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656403483?lang=zh_cn&edition=full","pubTime":"2026-08-03 12:30","pubTimestamp":1785731400,"startTime":"0","endTime":"0","summary":"南财智讯8月3日电，中国生物科技服务（08037.HK）发布自愿公告，公司附属公司鹏博(海南)硼中子医疗科技有限公司在第22届日本中子捕捉疗法学会学术大会（JSNCT22）上公布鹏博(海南)硼中子医院首批10例头颈癌患者硼中子治疗后三个月随访临床数据。结果显示，10例可评估患者中8例确认有效，完全缓解率40.00%（4例），部分缓解率40.00%（4例）。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608033829621344.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608033829621344.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1219","08037","BK1511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120848243","title":"中国生物科技服务（08037）宣布自2026年8月3日起变更百慕大注册办事处及股份过户登记总处地址","url":"https://stock-news.laohu8.com/highlight/detail?id=1120848243","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120848243?lang=zh_cn&edition=full","pubTime":"2026-07-28 16:42","pubTimestamp":1785228122,"startTime":"0","endTime":"0","summary":"中国生物科技服务控股有限公司（08037）7月28日发布公告称，公司将自2026年8月3日起变更其在百慕达的注册办事处、股份过户登记总处及过户代理地址，新地址为：Richmond House, 12 Par-la-Ville Road, Hamilton HM 08, Bermuda。\n公司同时披露，其位于香港的股份过户登记分处仍为联合证券登记有限公司，地址为香港北角英皇道338号华懋交易广场2期33楼3301-04室。\n公告由公司董事会主席兼执行董事刘小林代表董事会签署并发布。公告显示，截至公告日期，董事会由三名执行董事及三名独立非执行董事组成。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08037"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141104006","title":"中国生物科技服务6月股份变动月报表：股本保持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1141104006","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141104006?lang=zh_cn&edition=full","pubTime":"2026-07-03 16:17","pubTimestamp":1783066633,"startTime":"0","endTime":"0","summary":"中国生物科技服务于2026年7月3日发布截至2026年6月30日的证券变动月报表。公告显示，本月公司注册股本和实际已发行股份数均维持不变，股本整体保持稳定。已发行股份方面，截至6月底总数为975,731,150股，与5月底持平，且无库存股份变化。此外，本期无任何股份期权及股权激励计划的授出、行使或失效记录，亦未发生任何股份回购或注销。公司表示，目前已符合并将持续遵守香港联交所上市规则及相关法律法规要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08037"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173929153","title":"中国生物科技服务控股集团变更未来上市主体为鹏博（海南）并启动集团重组","url":"https://stock-news.laohu8.com/highlight/detail?id=1173929153","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173929153?lang=zh_cn&edition=full","pubTime":"2026-06-26 20:41","pubTimestamp":1782477675,"startTime":"0","endTime":"0","summary":"中国生物科技服务控股集团宣布，其未来上市主体将变更为鹏博（海南）有限公司，并同步启动集团内部重组计划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08037","BK1219","BK1511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193324075","title":"中国生物科技服务（08037）调整华大松禾3,000万元投资结构 持股鵬博（海南）降至88.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=1193324075","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193324075?lang=zh_cn&edition=full","pubTime":"2026-06-26 20:40","pubTimestamp":1782477640,"startTime":"0","endTime":"0","summary":"中国生物科技服务公告称，与华大松禾、鵬博（海南）硼中子医科技有限公司及相关方于2026年6月26日签署补充协议，重塑此前披露的3,000万元人民币投资交易架构。华大松禾完成转股后，持股比例降至88.19%，华大松禾持股6.25%，嘉博众治（海南）持股5.56%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08037"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ruikang.com.hk","stockEarnings":[{"period":"1week","weight":-0.0391},{"period":"1month","weight":-0.0682},{"period":"3month","weight":0.0982},{"period":"6month","weight":-0.1689},{"period":"1year","weight":-0.2849},{"period":"ytd","weight":-0.2215}],"compareEarnings":[{"period":"1week","weight":0.0119},{"period":"1month","weight":0.0225},{"period":"3month","weight":0.0036},{"period":"6month","weight":-0.0271},{"period":"1year","weight":0.0212},{"period":"ytd","weight":0.0027}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国生物科技服务控股有限公司（原名：锐康药业集团投资有限公司）是一家主要从事提供医学检测服务的投资控股公司。该公司通过六个分部运营业务。医学及保健相关服务分部主要提供医学实验室检测服务及健康检查服务。保险经纪分部主要提供保险经纪服务。免疫治疗分部主要提供肿瘤免疫细胞治疗、免疫细胞存储及健康管理服务。医药产品分部主要制造、研发、销售及分销保健相关及医药产品。证券分部主要从事买卖证券业务。其他分部主要从事放债业务及提供物流服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.181818,"avgChangeRate":-0.029278},{"month":2,"riseRate":0.5,"avgChangeRate":0.10268},{"month":3,"riseRate":0.363636,"avgChangeRate":-0.059753},{"month":4,"riseRate":0.272727,"avgChangeRate":-0.012084},{"month":5,"riseRate":0.681818,"avgChangeRate":0.094181},{"month":6,"riseRate":0.409091,"avgChangeRate":-0.024587},{"month":7,"riseRate":0.391304,"avgChangeRate":-0.011934},{"month":8,"riseRate":0.304348,"avgChangeRate":0.003236},{"month":9,"riseRate":0.181818,"avgChangeRate":-0.041523},{"month":10,"riseRate":0.318182,"avgChangeRate":0.014648},{"month":11,"riseRate":0.454545,"avgChangeRate":0.045242},{"month":12,"riseRate":0.5,"avgChangeRate":-0.009269}],"exchange":"SEHK","name":"中国生物科技服务","nameEN":"CH BIOTECH SER"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国生物科技服务(08037)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国生物科技服务(08037)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国生物科技服务,08037,中国生物科技服务股票,中国生物科技服务股票老虎,中国生物科技服务股票老虎国际,中国生物科技服务行情,中国生物科技服务股票行情,中国生物科技服务股价,中国生物科技服务股市,中国生物科技服务股票价格,中国生物科技服务股票交易,中国生物科技服务股票购买,中国生物科技服务股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国生物科技服务(08037)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国生物科技服务(08037)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}